Imeka AI-Powered White Matter Imaging

Exploring Neuroimaging with Imeka AI: Unveiling the Hidden World of White Matter

Imeka AI radiology software details white matter like never before, revolutionizing the way healthcare professionals and patients perceive it.

Imeka Radiology Solutions

At Imeka, expertise in white matter is second nature. Their cutting-edge imaging software offers unmatched clarity and precision. Reveal crucial diagnostic details with an unparalleled focus on neuroinflammation, axonal and myelin integrity, and overall white matter health.

Table of Contents
  1. Imeka Radiology Solutions
    1. Imeka ANDI
    2. Imeka ANIE
  2. Overview
    1. Additional Resources

Imeka’s approach centers on non-invasive, advanced white matter MRI techniques. Key features include:

  • Measure key neuropathological markers: neuroinflammation, axonal degeneration, and demyelination.
  • Gauge therapeutic effects like remyelination and tissue repair.
  • Conduct virtual dissection of 50+ distinct fiber bundles, even when dealing with complex fiber crossings.

Imeka ANDI

Imeka’s ANDI is a game-changer in microstructural white matter imaging for clinical use. ANDI encapsulates Imeka’s 12 years of expertise in high-performance diffusion MRI pipelines, previously harnessed by major pharmaceutical companies. Now, this expertise is harnessed in ANDI, providing Radiologists and Neurologists with vital information for evaluating brain damage in patients.

Through the fusion of advanced white matter imaging and artificial intelligence, Imeka proudly released the FDA-Cleared ANDI (Advanced Neuro Diagnostic Imaging) clinical software. This powerful software analyzes white matter with an unprecedented level of detail. It empowers healthcare professionals, particularly Neurologists and Radiologists, with comprehensive insights.

Imeka’s ANDI software enables informed decision-making for tailored treatment pathways based on its sophisticated white matter reports. Key features of ANDI software include:

  • Resilient CSD tracking against fiber crossings, offering enhanced macro-connectivity assessment.
  • Streamlined automated reporting in a secure cloud environment, minimizing intervention by MRI technologists.
  • Automated segmentation of 33 fiber tracts, serving as bundles of interest for micro-structure metric assessment.
  • Thorough comparison to normative references for each metric, benefiting from a growing pool of over 650 control subjects.
  • Rapid analysis using a single shell, 5-8 minutes acquisition sequence, compatible with 1.5T MRI or 3T MRI scan machines from any manufacturer.

Imeka ANIE

Specializing in neurodegenerative diseases, Imeka introduces the ANIE (Advanced Neuro Imaging Endpoints) biomarker platform. Designed to identify inflammation, demyelination, and axonal degeneration, the ANIE platform’s robustness against crossing fibers makes it an invaluable asset in conditions like Alzheimer’s, multiple sclerosis, and Parkinson’s disease.

Imeka’s ultimate vision is to uncover non-invasive and indirect markers sensitive to pathology, quantifying damage and therapeutic progress. The ANIE biomarker platform fulfills this vision flawlessly.

Our proprietary analytic algorithm collaborates seamlessly with well-trained artificial intelligence to identify and quantify white matter pathology and integrity.

  • Neuroinflammation: Imeka’s ANIE biomarker platform stands alone in identifying and quantifying neuroinflammation at the voxel level. This is achieved by assessing the free water fraction with remarkable sensitivity and specificity.
  • Imeka remains a pioneer, offering white matter microstructure assessment within specific fiber bundles.
  • The unique ANIE biomarker platform extracts 50+ primary white matter fiber bundles, enabling unprecedented virtual dissection capabilities. The microstructure analysis along each fiber bundle is entirely non-invasive.

Overview

Imeka’s biomarker potential is a game-changer, providing precise micro- and macrostructural insights into white matter well before clinical signs manifest. Imeka’s unwavering commitment to advancement is evident in the development of the ANIE biomarker platform over the last 12 years.

This platform offers novel biomarkers, enriching the capabilities of our clinical tool, ANDI, and is readily available to aid in assessing the efficacy of potential therapeutics within the brain.

Additional Resources